Page 59 - DUOKOPT BIBLIOBOOK

EFFICACY

Boyle et al Dorzolamide–Timolol Component Comparison in Washed-out Patients

Appendix patients with elevated intraocular pressure. Ophthalmology
1996;103:1283–93.
Members of the Dorzolamide–Timolol Study Group 3. Strahlman E, Tipping R, Vogel R, International Dorzolamide
Study Group. A double-masked, randomized 1-year study
Howard Barnebey, MD, Seattle, WA; Ronald Blitzer, MD, comparing dorzolamide (Trusopt), timolol, and betaxolol.
Rahway, NJ; Brian Bowe, MD, Wenatchee, WA; Charles Arch Ophthalmol 1995;113:1009–16.
Campbell, III, MD, Winston-Salem, NC; Leonard Ca- 4. Heijl A, Strahlman E, Sverrisson T, et al. A comparison of
cioppo, MD, Brooksville, FL; George Cioffi, MD, Portland, dorzolamide and timolol in patients with pseudoexfoliation
OR; John Cohen, MD, Cincinnati, OH; Marshall Cyrlin, and glaucoma or ocular hypertension. Ophthalmology 1997;
104:137–42.
MD, Southfield, MI; Robert Friedman, MD, Sunrise, FL;
Marvin Greenberg, MD, Ft. Lauderdale, FL; David Gieser, 5. Kass MA, Gordon M, Morley RE Jr, et al. Compliance
with topical timolol treatment. Am J Ophthalmol 1987;103:
MD, Wheaton, IL; Louis Gottlieb, MD, Winston-Salem, 188–93.
NC; Frank Grady, MD, Lake Jackson, TX; Donald Guber, 6. Cramer JA, Mattson RH, Prevey ML, et al. How often is
MD, Altamonte Springs, FL; Barton Hodes, MD, Tucson, medication taken as prescribed? A novel assessment tech-
AZ; Alfred Jolson, MD, Altamonte Springs, FL; Stefan nique. JAMA 1989;261:3273–7.
Karas, MD, Honolulu, HI; David Karp, MD, Melvyn Koby, 7. Cramer J, Vachon L, Desforges C, Sussman NM. Dose fre-
MD, Louisville, KY; Kristine Kunesh–Part, MD, Dayton, quency and dose interval compliance with multiple antiepi-
OH; Robert Laibovitz, MD, Austin, TX; Richard Lewis, leptic medications during a controlled clinical trial. Epilepsia
MD, Sacramento, CA; Charles McMahon, MD, Colorado 1995;36:1111–7.
Springs, CO; Thomas Mundorf, MD, Charlotte, NC; Leo- 8. Data on file. Whitehouse Station, NJ: Merck and Co., Inc.
nard Parver, MD, Washington, DC; Michael Rotberg, MD, 9. Sturm A, Vogel R, Binkowitz B, Timolol–Pilocarpine Clinical
Charlotte, NC; Joel Schuman, MD, Boston, MA; John Sta- Study Group. A fixed combination of timolol and pilocarpine:
bile, MD, Tenafly, NJ; Jacob Wilensky, MD, Chicago, IL. double-masked comparisons with timolol and with pilo-
carpine. J Glaucoma 1992;1:7–13.
10. Sears ML, ed. Pharmacology of the Eye. Berlin; New York:
References Springer–Verlag, 1984;303 (Handbook of experimental phar-
macology; v. 69).
1. Vaughan D, Riordan–Eva P. Glaucoma. In: Vaughan D, As- 11. Neufeld AH, Bartels SP, Liu JHK. Laboratory and clinical
bury T, Riordan–Eva P, eds. General Ophthalmology, 14th ed. studies on the mechanism of action of timolol. Surv Ophthal-
Norwalk, CT: Appleton & Lange, 1995; chap. 11. mol 1983;28:286–90.
2. Strahlman ER, Vogel R, Tipping R, et al. The use of dorzo- 12. Neufeld AH. Experimental studies on the mechanism of action
lamide and pilocarpine as adjunctive therapy to timolol in of timolol. Surv Ophthalmol 1979;23:363–70.

1951

59